Skip to content

Standard Biotools Inc.

LAB· NasdaqCore metricsCIK 1162194

Pharmaceutical preparations553 peers

Last sale
Nov 12, 2026 · +0.35%
Market cap
$257.88M
394.79M shares
Filings
1,055
$19.39M
Q3 2026−6.2% FY25 yoy
$13.48M
Q3 2026N/M FY25 yoy
-$19.77M
Q3 2026N/M FY25 yoy
-$63.98M
Q3 2026derivedN/M FY25 yoy
$0.03
Q3 2026N/M FY25 yoy
$267.49M
Q3 2026−27.5% FY25 yoy
$257.88M
1.9×
3.1×
0.5×
-25.46%
—

Twelve months to Sep 30, 2026 · derived

Price

$0.653245.34%$0.5418past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$85.33MFY 2025
$138.14M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$85,331,000reported
FY 20242024-12-31$91,008,000 revisedreported
FY 20232023-12-31$106,340,000reported
FY 20222022-12-31$97,948,000reported
FY 20212021-12-31$130,581,000reported
FY 20202020-12-31$138,144,000reported
FY 20192019-12-31$117,243,000reported
FY 20182018-12-31$112,964,000reported
FY 20172017-12-31$101,937,000reported
FY 20162016-12-31$104,446,000reported
FY 20152015-12-31$114,712,000reported
FY 20142014-12-31$116,456,000reported

Capital returns

Dividends and buybacks · FY2021 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$0.00$0.00—390.07M sh+2.9%—
FY2024—$40.49M$40.49M—378.99M sh+0.0%—
FY2023—$5.41M$5.41M—378.86M sh+379.2%—
FY2022—$563.00K$563.00K—79.06M sh+2.4%—
FY2021—$0.00$0.00—77.20M sh+3.6%—

Segments

Revenue by Segments, FY2021 to FY2024FY2021Genomics · FY2021 · $62.92MProteomics · FY2021 · $67.66MFY2022Proteomics · FY2022 · $52.50MGenomics · FY2022 · $45.45MGenomics · FY2022 · $45.45MProteomics · FY2022 · $52.50MFY2023Proteomics · FY2023 · $63.88MGenomics · FY2023 · $42.46MFY2024Proteomics · FY2024 · $135.79MGenomics · FY2024 · $38.64M
LineFY2024ShareChange
Proteomics$135.79M149%+112.6%
Genomics$38.64M42%−9.0%
Genomics———
Proteomics———
Total$91.01M

From the 10-K filed Mar 11, 2025LAB

Pharmaceutical preparations

Standard Biotools Inc. is the 105th largest of the 554 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR